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Abstract
This study investigated the effects of pregnane X receptor (PXR/NR1I2) and CYP2B6 genetic variants on sodium ferulate (SF)-
mediated induction of bupropion hydroxylation. The pharmacokinetics of bupropion and hydroxybupropion were
evaluated after an oral dose of bupropion (150 mg) administered with and without SF pretreatment for 14 days in 33
healthy subjects. The area under the time-concentration curve (AUC) ratio of AUC_hyd (AUC(0-‘) of hydroxybupropion)/
AUC_bup (AUC(0-‘) of bupropion) represents the CYP2B6 hydroxylation activity, which was significantly lower in CYP2B6*6
carriers (NR1I2 TGT noncarriers or carriers) than in noncarriers in both the basal and SF-induced states (p-value,0.05). AUC
ratio and AUC_hyd of NR1I2 -24113AA variant were markedly lower than GA and GG genotypes (7.562.1 versus 14.563.3
and 20.661.1, and 887361431 versus 14,50462218 and 17,58661046) in the induced states. However, -24020(-)/(-) variant
didn’t show significant difference in the induction of CYP2B6 hydroxylation activity by SF compared with other
-24020[GAGAAG]/(-) genotypes. NR1I2 TGT haplotype (-25385T+g.7635G+g.8055T) carriers exhibited a significantly
decreased AUC ratio, compared with TGT noncarriers, in the basal states (7.661.0 versus 9.761.0), while this result wasn’t
observed in CYP2B6*6 noncarriers. Moreover, individuals with complete mutation-type [CYP2B6*6/*6+NR1I2 TGT+
-24113AA+ -24020 (-)/(-)] showed even lower percent difference of AUC ratio (8.761.2 versus 39.568.2) than those with
complete wild-type. In conclusion, it is suggested that NR1I2 variants decrease the bupropion hydroxylation induced by SF
treatment, particularly in CYP2B6*6 carriers.
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Introduction
Human pregnane X receptor (hPXR) may regulate metabolic
pathways in response to changes in the environment by
appropriate alterations in gene expression of key metabolic
enzymes [1]. hPXR is a member of the nuclear receptor
superfamily, and encoded by the NR1I2 gene, which is located
in the chromosome 13q11-13 and composed of nine exons. It
consists of 434 amino acids with a molecular weight of 49.7 kDa
[2]. It is abundantly expressed in liver and intestine, and plays an
important role in ligand-activated transcription and regulation of
genes involved in xenobiotic and endobiotic metabolism [3–5].
The transcriptional activity of NR1I2 is mediated through the
ligand binding pathway. Many chemical drugs, including rifampin
[4,5], phenobarbital [6,7], dexamethasone [7,8], and herbs such as
Kava [7], St. John’s wort (hyperforin) [9,10], and Ginkgo biloba
extract (ginkgolide A) [11] have been verified as regulators of
NR1I2 transcriptional activity. Meanwhile, hPXR binds to DNA
response elements as a heterodimer with the 9-cis retinoid X
receptor (RXRa) [12] and acts as a transcriptional regulator of
many important genes that are encoding drug-metabolizing
enzymes, such as phase I enzymes (e.g., CYP3A4, 3A5, 2A6, 2B6,
2C9, 2C19, and 1A1), phase II enzymes (e.g., UGT1A1, 1A3, 1A4,
and 1A6), and phase III enzymes (e.g., MDR1, MRP2, and
OATP1B1) [13–15].
The genetic variants of NR1I2 affect the disposition and
interaction of various drugs through an induction pathway of
CYPs, which may explain the interindividual difference of PXR
activity [16,17]. Previous studies showed that variant alleles of
NR1I2 single nucleotide polymorphisms (SNPs) -25385C.T
(rs3814055), -24113G.A (rs2276706), g.7635A.G (rs6785049),
or g.8055C.T (rs2276707) were associated with increased NR1I2
transcriptional activity [18], and -24020[GAGAAG].(-)
(rs3842689) completed loss of NR1I2 promoter activity in HepG2
cells [19]. NR1I2 TGT haplotype (-25385T+g.7635G+g.8055T)
and -25385C.T variants were also reported to be associated with
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reduced induction of bupropion hydroxybupropion by rifampin
[20]. However, these controversial results of NR1I2 variants
functions in vitro and in vivo have not been consistently validated.
Sodium ferulate (3-methoxy-4-hydroxy-cinnamate sodium,
C10H9NaO4, SF) is the sodium salt of ferulic acid (FA), which is
widely distributed in herbs and Chinese formulas such as
Ligusticum, Chuanxiong and Chaihu–Sugan–San [21,22]. It is
usually used as food supplements or herbal medicine in countries
or areas accepting the theory of Traditional Chinese Medicine
(TCM). With the anti-oxidant, anti-atherogenic, anti-platelet
clotting, anti-inflammatory, lipid-lowering, cholesterol biosynthesis
inhibitory and analgesic effects [23–26], FA has the potential to be
developed into an effective pure compound for prevention and
treatment of cardiovascular diseases. Presently, SF has been
approved by State Food and Drugs Administration of China
(SFDA) as a clinical therapy for cardiovascular and cerebrovas-
cular diseases [27,28].
Combination of SF and CYP2B6 substrate drugs has the
potential possibility of drug-drug interactions and may lead to
undesirable and harmful clinical consequences. Although human
CYP2B6 represents approximately 1% of total hepatic CYP
content, it shows a relative contribution of 2% to 10% in total
hepatic CYP activity, and participates in the metabolism of a
variety of substances including bupropion, selegiline, valproic acid,
cyclophosphamide, ifosfamide, nevirapine, efavirenz, propofol,
ketamine, and synthetic opioid methadone [29]. In particular, the
metabolic pathway of hydroxybupropion is almost exclusively
catalyzed by CYP2B6 that is a standard model for studies of drug-
drug interactions of CYP2B6 substrate drugs [30–33]. Recently,
we verified that bupropion hydroxylation metabolism (represents
CYP2B6 metabolism activity) was induced by a 14 days pre-
treatment of 150 mg SF in healthy volunteers [34]. Our previous
investigations in HepG2 cells suggested that FA may increase 67%
transcriptional expression of CYP2B6 through PXR activation
compared with control group (unpublished data). Due to
frequently combinational use, especially in China, of SF and
other drugs during the treatment of clinical diseases, it is important
to be aware of the possibility of interactions of combination of SF
and CYP2B6 substrate drugs, and to prevent harmful clinical
toxicity.
Effects of CYP2B6 variations on protein expression levels and
enzyme activities may cause up to hundreds fold of interindividual
difference in exposure to drugs [35]. Early studies indicated
CYP2B6*6 carriers contributed to the interindividual difference in
CYP2B6 substrate drugs disposition [36,37]. The low-activity and
high-frequency of allele CYP2B6*6 was very prevalent in African
Americans (32.8%), Papua New Guineans (62%) and Asians (21%)
[35]. It can be simply speculated that the number of abnormal
population of CYP2B6 variants will be marked, when other
CYP2B6 functional variants are added. Therefore, it is very critical
to investigate whether CYP2B6 variants effect the induction of
bupropion hydroxylation by SF.
Based on above studies, SF-induced CYP2B6 activity is
suggested to be associated with both CYP2B6*6 polymorphisms
and other factors such as NR1I2 genetic variants. Furthermore,
both NR1I2 and CYP2B6 variants may be associated with the
clinical pharmacokinetics and/or interactions of SF and bupropi-
on. However, clinical pharmacogenetics study data of NR1I2 and
CYP2B6 variants is still scarce. Further studies are still necessary to
investigate the functions of NR1I2 and CYP2B6 genetic variants in
clinic. The purpose of this paper is to evaluate the effect of NR1I2
and CYP2B6 genetic variants, and to demonstrate the relationship
between these genetic variants and metabolic induction of
bupropion hydroxylation by SF administration in Chinese
individuals.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Genotyping
Genomic DNA was isolated from peripheral blood samples
using SQ Blood DNA KitII(Omega Bio-Tic, Georgia, USA).
NR1I2. NR1I2 -25385C.T (rs3814055), -24113G.A
(rs2276706), -24020 [GAGAAG].(-) (rs3842689), g.7635A.G
(rs6785049) and g.8055C.T (rs2276707) were amplified by
polymerase chain reaction (PCR) and genotyped. The sequences
of forward and reverse primers were 59-CAAGGCAAGCATC-
CACTTGA -39, 59- GTTGAT- TCTGTTCACTTGGG-39 for -
25385C.T, 59- AGGCAGCGGCTCCTTGGTAA -39, 59-AG-
GACAGCAGCATGA- CAGTC-39 for -24113G.A and -
24020[GAGAAG].(-), 59- CAAGCTCAGTGGGTG- GAGTT
-39, 59- TTCTCCCCAGGTGAGGATCT-39 for g.7635A.G
and g.8055C.T, respectively. The PCRs used a thermocycling
profile of initial denaturation at 95uC for 5 min, followed by 30
cycles of denaturation at 95uC for 30 s, annealing at 55uC for 30 s
and extension at 72uC for 1 min. The final volume of the PCR
was 50 ml , consisting of 20 ng of DNA, 10 mM of each primer
pair, 2.5 mM of dNTPs, 5 ml of 106 reaction buffer, and 2.5 U of
Taq DNA polymerase (MBI Fermentas, Ontario, Canada). SNPs
were identified by DNA sequencing according to a standard
protocol with ABI PRISM Big Dye Terminator Cycle Sequencing
Ready Reaction Kit and ABI 3700 DNA Analyzer (Applied
Biosystems, Foster City, California, USA).
CYP2B6. The wild-type allele CYP2B6*1 was defined as 516G/
785A, and CYP2B6*6 was defined as 516T/785G. CYP2B6*6 was
detected in a haplotype assay using a two-step allele-specific PCR
as described previously [38]. The validity of the method was
confirmed by sequencing.
Subjects
To detect NR1I2 and CYP2B6 genetic polymorphisms in the
Chinese population, a total of 152 individual samples (from the
DNA bank, Hunan Key laboratory of Pharmacogenetics, Central
South University) were genotyped. Thirty-four healthy male
volunteers (eighteen CYP2B6*1/*1, nine CYP2B6*1/*6 and seven
CYP2B6*6/*6) were enrolled in the clinical trial with informed
consent form signed (aged 20 to 24 years; weight range: 52–77 kg;
body mass index range: 18–25 kg/m2), and divided into
CYP2B6*6 noncarriers (CYP2B6*1/*1, wild-type) and CYP2B6*6
(CYP2B6*1/*6+CYP2B6*6/*6) carriers. The health status of
subjects were ascertained by checking medical history and taking
a full clinical examination, drug screening, and standard
hematologic and blood chemical laboratory tests. Standardized
protein-rich diets with no vegetables, fruits or cereals were
provided for subjects for 2 weeks prior to study and during the
whole study, in order to exclude the influence of food-originated
FA. Drugs, alcohol, soft drinks, tobaccos, vitamins and caffeine-
containing beverages, any nutritional supplements were refrained
for 2 weeks before study commencement and throughout the
study. Regular heavy drinkers, smokers, users of glucocorticoids
and those with body weight exceeded their ideal weight by 20%
were excluded. Finally, 33 of recruited subjects finished the trial
(the date range of subject enrollment was from April 24, 2011 to
July 25, 2011).
Pharmacogenetics of PXR and CYP2B6
PLOS ONE | www.plosone.org 2 June 2013 | Volume 8 | Issue 6 | e62489
This study was approved by the ethics committee of Central
South University, Changsha, Hunan, P. R. China (approved
number: CTXY- 110003) and registered in the Chinese Clinical
Trial Registry (registration number: ChiCTR-TRC -11001285,
name: The effect of ferulic acid on metabolism of bupropion by
CYP2B6). Overall clinical trial procedures abided by the Good
Clinical Practice of the International Conference on Harmoniza-
tion (ICH-GCP).
Study Design
This study was carried out in a two-phase, randomized,
crossover manner with a 2-week washout period between phases.
In each phase, after an overnight fast, subjects were given
pretreatment with or without three 50-mg SF tablets (one tablet,
three times a day) of the same batch (Lot No.: 100810; HengDa
ShengKang Pharmaceutical Co., Sichuan, China) for fourteen
days. The signature of subjects, supervision of investigators and
detection of plasma concentrations of FA were carried out to
assure subject compliance to treatment. On day 15, after an
overnight fast, a single dose of 150 mg bupropion (two tablets of
75 mg Zyban SR; WanTe, Hainan, China) was given to each
subject by oral administration with 200 ml water at 8:00 a.m.
Subjects fasted for another 4 h after drug administration, except
water drinking 2 h after dosing. Standard meals were provided for
all of the participants. Serial blood samples for PK analysis (5 ml)
were collected using a forearm in-dwelling venous catheter
(anticoagulation with sodium heparin) before dosing and at 0.5,
1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 60 and 72 h after bupropion
ingestion.
Drug Concentration Analysis
The plasma concentrations of bupropion and hydroxybupro-
pion were examined by liquid chromatography–mass spectrome-
try using Waters Micromass Quattro Micro API LC/MS/MS
instrument (Milford, MA, USA). An Angel kromasil C18 (5 mm,
15062.1 mm) and a mobile phase (acetonitrile:0.1% formic
acid:20 mM ammonium formate = 4:3:3) at a flow rate of
0.2 ml/min were applied. Propranolol was used as the internal
standard. The ion transitions monitored were as follows: m/z 240
to 184 for bupropion,m/z 256 to 238 for hydroxybupropion and
m/z 260 to 183 for propranolol. These transitions represent the
product ions of the [M+H]+ ions. The lower limits of detection for
bupropion and hydroxybupropion were 0.25 ng/ml and
1.168 ng/ml, and the assay ranges used were 0.42–430.1 ng/ml
and 2.344–1200 ng/ml, respectively. The linear correlation
coefficient for bupropion calibration curves was 0.998, and for
hydroxybupropion was 0.996. The highest bupropion and
hydroxybupropion plasma concentration measured were
323.70 ng/ml and 615.66 ng/ml. The mean extraction recovery
and precision of bupropion and hydroxybupropion was assessed
by determining quality control (QC) plasma samples at three
concentration levels (concentrations of bupropion and hydroxy-
bupropion were 2.344, 37.5, 600 ng/ml and 0.84, 13.438,
430 ng/ml, respectively). The recovery of bupropion and hydro-
xybupropion, determined at each concentration level was
92.167.1, 9365.3, 91.863.6 and 90.664.7, 91.564.8,
92.466.3 (%, n = 5), respectively, and did not exceed 10% of
the relative standard deviation (R.S.D.). The precision (R.S.D.) of
bupropion at three concentration levels in intra-day and inter-day
was 8.67, 5.67, 7.32 (%) and 4.19, 6.57, 8.92 (%), respectively.
Similarly, the precision (R.S.D.) of hydroxybupropion in intra-day
and inter-day was 7.34, 3.58, 8.49 (%) and 4.25, 7.13, 9.12 (%),
respectively. The precision of both bupropion and hydroxybupro-
pion was less than 10% of R.S.D.
Pharmacokinetic Analysis
The maximum plasma concentration (Cmax) and the time to
Cmax (Tmax) were obtained by inspection of the concentration-time
data. The AUC to the last quantifiable concentration AUC0-t was
determined by use of the linear trapezoidal rule. ke is the
elimination rate constant determined from the terminal slope of
the log concentration-time plot. The elimination half-life (t1/2) was
calculated as 0.693/ke. The area under the concentration-time
curve extrapolated to infinity AUC0-‘ was calculated as AUC0-‘
= AUC0–72+C72/ke, where C72 is the plasma concentration
measured 72 h after drug administration. The oral clearance
(CL/F) of bupropion was calculated by dividing the bupropion
dose by the AUC of bupropion and the subject’s weight.
Statistical Analysis
Study sample sizes were estimated based on prior bupropion PK
data. The planned sample size, statistical power, and alpha level
were performed using the NCSSV2007 program. For instance, if
three subjects in TGT carriers for CYP2B6*6 noncarriers group
were enrolled, the power (AUC ratio) is up to 0.92371 (a= 0.05,
b= 0.2) according to prior bupropion PK data. Likewise, in TGT
carriers for CYP2B6*6 carriers group, if five subjects participated
in this study, the power will add to 0.93165 (a= 0.05, b= 0.2)
(calculation methods as described NCSS2007 instruction). The
bioequivalence approach was used to determine clinically relevant
interactions [39]. AUC ratio, namely AUC_hyd (AUC(0-‘) of
hydroxybupropion) was divided by AUC_bup (AUC(0-‘) of
bupropion) for each period, representing CYP2B6 activity. The
percent differences in the PK parameters between the basal and
SF-treated states were calculated as an absolute of 1006(induced-
basal)/basal. WinNonlin (version 5.2; Pharsight, Mountain View,
CA) was used for the PK analysis. The paired two-tailed t-tests
were used to determine the difference between basal and induced
states, and logarithmic transformation was used for the non–
normally distributed data before analysis. The differences in PK
parameters between noncarriers and carriers groups of NR1I2
TGT haplotype and CYP2B6*6 genotypes were obtained using the
Wilcoxon rank-sum test. The difference among NR1I2 -25385C
.T (CC, CT and TT) and -24113G.A (GG, GA and AA) genotype
groups was obtained by use of the Kruskal-Wallis test. The Fisher’s
exact test was used to detect difference of genotype distributions
between CYP2B6*1/*1 and CYP2B6*1/*6+CYP2B6*6/*6. Results
were expressed as mean 6 standard deviation in the text and
tables, and as mean 6 standard error in the figures. Linkage
disequilibrium (LD) analysis and haplotype construction were
performed using the Haploview 4.2 program (Broad Institute of
Harvard and MIT, Cambridge, MA) and Phase 2.0 (UW Center
for Commercialization; University of Washington), Data were
analyzed with SPSS software (IBM SPSS; version 13.0). The
chosen statistical significance level was p,0.05.
Results
Genetic Polymorphisms of NR1I2 in the Chinese
Population
The frequencies of NR1I2 alleles -25385T, -24113A, -24020(-),
g.7635G and g.8055T were 0.283, 0.181, 0.208, 0.522, and 0.625,
respectively. The distribution of those genotypes was consistent
with Hardy-Weinberg equilibrium (p-value .0.05, x2 test). NR1I2
-25385C.T, -24113G.A, and -24020[GAGAAG].(-) displayed
a slight LD (r2$0.56). Also, NR1I2 g.7635A.G and g.8055C.T
showed a slight LD (r2$0.62). In view that compared with
previous NR1I2 haplotypes investigation, we selected three SNPs -
25385C.T, g.7635A.G, and g.8055C.T to perform haplotype
Pharmacogenetics of PXR and CYP2B6
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analysis, and eight haplotypes were inferred based on these SNPs
in Chinese: CAC, CGT, TGT, TAC, CGC, TGC, CAT, and
TAT. The population frequencies of these haplotypes were 0.221,
0.491, 0.136, 0.035, 0.073, 0.043, 0.001 and 0.000, respectively.
CAC haplotype was regarded as the wild-type allele, and TGT
haplotype was the mutation-type allele. The subjects were divided
into TGT carrier (n = 10) and noncarrier (n = 23) groups, based on
the existence of NR1I2 TGT haplotype or not.
Results of the Clinical Study
According to the ICH-GCP guideline [40], no serious drug-
related adverse event was observed from the 33 subjects during the
course of this study. No clinically significant alterations were
observed in heart rate, blood pressure or body temperature. No
significant difference was shown in the demographic characteris-
tics of the volunteers or in the distributions of CYP2B6 genotypes
among NR1I2 haplotypes (see Table 1).
After SF treatment, in complete wild-type groups, AUC_bup
was significantly lower (657673 versus 8536102), while AU-
C_hyd was significantly higher (15,59462799 versus
12,73262448). The AUC ratio (AUC_hyd/AUC_bup), which
represents the metabolic activity of bupropion into hydroxybu-
propion, markedly increased (17.762.1 versus 13.161.7, see
Table 2). However, No significant difference was shown in
-24113AA, -24020(-)/(-), and TGT carriers (CYP2B6*6 carriers),
AUC_hyd and AUC ratio after SF treatment (p-value.0.05,
paired t test, see Table 3 and 4). Furthermore, in -24113AA
variant, AUC ratio and AUC_hyd was significantly lower
(7.562.1 versus 14.563.3 and 20.661.1, and 887361431 versus
14,50462218 and 17,58661046) than -24113GA and GG
genotypes in the induced states. Moreover, -24113 AA variant also
showed significantly lower AUC ratio (6.860.7 versus 11.362.5
and 15.560.8) than -24113GA and GG genotypes in the basal
states (see Table 3). Further research found that -24020(-)/(-) variant
only showed slight difference (889561328 versus 15,11661797 and
15,51861168, p-value.0.05) in AUC_hyd in the induced states
compared to other -24020[GAGAAG]/(-) genotypes, and no
significant impact was shown on the induction of bupropion
hydroxybupropion by SF compared with other -24020[GA-
GAAG]/(-) genotypes.
The effects of CYP2B6 genotypes and NR1I2 TGT haplotype
were considered as a whole and are showed by subgroups (see
Table 4). CYP2B6*6 carriers always showed significantly lower
AUC ratio than that of noncarrier group in both the basal and
induced states, and also in TGT noncarrier or carrier groups.
NR1I2 TGT carriers (CYP2B6*6 carriers) had a significantly lower
AUC ratio and percent difference of AUC ratio (7.661.0 versus
9.761.0, and 17.169.5 versus 23.267.0) than noncarriers.
However, there was no significant difference observed in AUC
ratio and percent difference of AUC ratio between NR1I2 TGT
carrier and noncarrier groups for CYP2B6*6 noncarriers.
Furthermore, TGT carriers (CYP2B6*6 noncarriers) had signifi-
cantly lower percent difference of AUC_hyd (18.165.2 versus
32.566.5) than noncarriers, while there was no significant
difference in CYP2B6*6 carriers (see Table 4). In addition, the
complete mutation-type [CYP2B6*6/*6+NR1I2 TGT+
-24113AA+-24020(-)/(-)] individuals exhibited even lower percent
difference of AUC ratio (8.761.2 versus 39.568.2) than those of
complete wild-types (p-value,0.05, see Table 2).
As shown in Fig. 1, individual plots of CYP2B6 and NR1I2
variants indicated that the combination of NR1I2 TGT haplotype
and CYP2B6*6 affected the AUC ratio in both the basal and
induced states. The concentration-time profiles of hydroxybupro-
pion were very different for CYP2B6*6+NR1I2 TGT carriers from
other groups, with the lowest values in both the basal and induced
states (see Fig. 2). The Cmax values of hydroxybupropion in the
basal and induced states showed no significant difference between
NR1I2 TGT carriers and noncarriers (unpublished data). Howev-
er, the hydroxybupropion Cmax in CYP2B6*6+NR1I2 TGT
carriers was significantly lower than CYP2B6*6+NR1I2 TGT
noncarriers in both the basal and induced states (284.3640.8
versus 395.2640.5, and 332.9627.6 versus 424.5632.8, p-
value,0.05).
Discussion
In the present study, we investigated the NR1I2 genetic
polymorphism in Chinese population and found that the allelic
frequencies of -25385T and -24113A in Chinese (0.283, 0.181)
were lower than the reported frequencies of Korean (0.32, 0.32),
European descent (0.39, 0.32), and Africa American (0.39, 0.32)
[18,20]. The allelic frequency of -24020(-) was significantly lower
(0.218) than that of Japanese (0.274) and Korean (0.319) [19,20],
and the allelic frequency of g.7635G was an intermediate value
(0.522) between European descent (0.35) and Africa American
(0.77). However, g.8055T has markedly higher (0.625) allele
frequency compared with that in Brazilian (0.125), European
descent (0.15), African (0.18), Indian (0.24), Korean (0.41), and
Malay (0.43) [18,20,41,42]. The NR1I2 allelic frequency observed
in this study was very similar to the previous report in Chinese
[43].
Further haplotypes analysis showed that compared with the
Korean, the composition and frequencies of NR1I2 TGT
haplotypes in Chinese people were completely different. Eight
haplotypes were inferred based on SNPs in positions -25385C.T,
g.7635A.G, and g.8055, and the frequency distribution of TGT
haplotype was slightly lower (0.136) than that of Korean (0.199).
Furthermore, linkage manners of NR1I2 SNPs were inconsistent
with the Korean. A slight but not complete LD among
-25385C.T, -24113G.A, and -24020[GAGAAG].(-) and
between g.7635A.G and g.8055C.T was observed [20]. These
results suggest that the NR1I2 gene has unique characteristics of
high polymorphism and significant interethnic variants.
As shown in Table 4, we found in the clinical investigation that
in TGT noncarriers (TGT noncarriers, n = 14), the overall
pharmacokinetic parameters of bupropion and hydroxybupropion
(AUC_bup, AUC_hyd, and AUC ratio) indicated the strongest
effects including basal activities, induced activities and their
percent differences. However, with the emergence of TGT and
CYP2B6*6 variants (TGT carriers, n = 4 and TGT noncarriers,




(n = 10) p
Age (yr) 2260.6 2160.3 0.105a
Weight (kg) 6361.7 6262.3 0.384a
High (cm) 1.7060.01 1.7160.02 0.603a
BMI (kg/m2) 22.060.4 21.760.5 0.124a
2B6*1/*1 (18) 14 4 0.448b
2B6*1/*6 (9)+*6/*6 (6) 9 6
aWilcoxon rank-sum test between TGT Noncarriers and TGT Carriers groups.
bFisher’s exact test between CYP2B6*1/*1 and CYP2B6*1/*6+CYP2B6*6/*6,
X2 = 1.224, p = 0.448. BMI: body mass index.
doi:10.1371/journal.pone.0062489.t001
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n = 9, respectively), the strongest effects of the overall pharmaco-
kinetic parameters of bupropion and hydroxybupropion became
weaker and smaller, until TGT variant existed in CYP2B6*6
carriers (TGT carriers, n = 6). Moreover, in each step of the
attenuation effects of the pharmacokinetic parameters, TGT and
CYP2B6*6 carriers always showed smaller effects than noncarriers.
Therefore, this result suggests that the decreased metabolism of
bupropion with SF treatment is affected by both NR1I2 TGT and
CYP2B6*6 variants. Also, similar findings were obtained from
-24113G.A, -24020 [GAGAAG]. (-), and complete wild/
mutation-type individuals (see Table 2 and 3). In short, our data
strongly support the hypothesis that NR1I2 TGT haplotype,
-24113AA, and CYP2B6*6 variants play very important roles in
bupropion disposition.
Interestingly, in previous study, NR1I2 TGT carriers slightly
manifested stronger effects on some pharmacokinetics parameters
of bupropion and hydroxybupropion than the corresponding
noncarrier groups (p-value.0.05). Conversely, CYP2B6*6 carriers
showed smaller effects on AUC_hyd, and AUC ratio than the
noncarriers (p-value,0.05) [20]. Reports also showed that
CYP2B6 expression increased in the basal state while decreased
in the induced state when treated with rifampin in PXR.2 cells
[44]. However, these results were not observed in our study.
Rifampin is a known selective human PXR activator with little
cross-interaction with other receptors, such as small heterodimer
Table 2. Effects of complete wild-type and mutation-type individuals on SF-mediated metabolic induction of bupropion
hydroxylation.












% differenceb 39.568.2* 8.761.2a
*p,0.01, paired t test between the basal and induced states.
ap,0.05, Wilcoxon rank-sum test between [CYP2B6*1/*1+NR1I2 CAC + -24113GG+-24020[GAGAAG]/[GAGAAG]] (complete wild-type) and [CYP2B6*6/*6+NR1I2 TGT+ -
24113AA+-24020(-)/(-)] (complete mutation-type) groups.
b% difference represents the percent difference between basal and induced state, calculated as an absolute of 1006(induced-basal)/basal.
doi:10.1371/journal.pone.0062489.t002
Table 3. Effects of NR1I2 SNP polymorphisms on SF-mediated metabolic induction of bupropion hydroxylation.




[GAGAAG] (n = 22)
-24020[GAGAAG]/




Basal 977664 10626136 11386207 1011664 11146131 11256186
Induced 960655 10316169 10836206 995653 10006157 10866214
% differenceb 8.961.5 0.660.4 0.560.3 6.861.3 4.360.5 1.260.4
AU C(0–‘)_hyd (ng?h/ml)
Basal 13,2966881 11,60161367 812661573 12,0636952 11,81461101 818561436
Induced 17,58661046 14,50462218 887361431a 15,51861168 15,11661797 889561328
% differenceb 32.065.1* 27.966.9* 12.566.3 31.265.3* 28.066.0* 17.564.7
AUC_hyd/AUC_bup
Basal 15.560.8 11.362.5 6.860.7a 12.461.0 11.961.9 7.360.8
Induced 20.661.1 14.563.3 7.562.1a 16.861.2 15.663,1 9.562.0
% differenceb 34.465.0* 30.666.3* 11.367.9 39.465.2* 28.664.9* 20.668.5
*p,0.01, paired t test between the basal and induced states.
ap,0.05, Kruskal-Wallis test for NR1I2 -24113G.A and -24020[GAGAAG].(-) groups.
b% difference represents the percent difference between basal and induced state, calculated as an absolute of 1006(induced-basal)/basal.
doi:10.1371/journal.pone.0062489.t003
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partner (SHP) and hepatocyte nuclear factor-4a(HNF-4a) [45,46].
Early study indicated that interaction of PXR with HNF-4aand its
coactivators, peroxisome proliferator-activated receptor-c-coacti-
vator-1a(PGC-1a) contributed to the strong induction of CYP3A4
by rifampin, whereas gene expression of SHP was simultaneously
inhibited by PXR, which weakened inhibitory effect of SHP on
CYP3A4 expression and strengthened the HNF-4ainducibility of
CYP3A4 [45,47]. Therefore, we may assume that under the
situation that some interfering factors of SHP gene expression
exceeded the effects of PXR variants (PXR function variant led to
increased SHP gene expression), the activity of CYP did not
decline but increased. More attention should be paid to the study
of SHP gene expression and regulation in the near future.
Moreover, Owen’s group reported that genetic variability in
constitutive androstane receptor (CAR) was involved in the
metabolism and disposition of CYP2B6 substrate drugs recently
[48].
In our study, further analysis showed that TGT carriers, only in
the basal states, had significantly lower AUC ratio and percent
differences (7.661.0 versus 9.761.0, and 17.169.5 versus
23.267.0) than TGT noncarriers. However, CYP2B6*6 carriers
exhibited significant differences in the most of pharmacokinetic
Table 4. Effects of NR1I2 haplotype and CYP2B6 genotypes on SF -mediated metabolic induction of bupropion hydroxylation.
CYP2B6*6 noncarriers (wild-type) (n = 18) CYP2B6*6 carriers (n = 15) pd
TGT Noncarriers
(n = 14) TGT Carriers (n = 4) TGT Noncarriers (n = 9) TGT Carriers (n = 6)
AUC(0–‘)_bup (ng?h/ml)
Basal 869663 924673 11866100b 12476161 0.004
Induced 800699 898651 1175681b 1194690 0.002
% differencee 7.960.8 2.860.5 2.260.8 1.060.8 0.229
AU C(0–‘)_hyd (ng?h/ml)
Basal 12,48461239 12,05761100 11,48561499 88446822c 0.044
Induced 16,75961624 14,0786676 14,03061891 11,02961225c 0.021
% differencee 32.566.5* 18.165.2a 24.969.1* 24.467.5 0.048
AUC_hyd/AUC_bup
Basal 14.561.5 13.961.1 9.761.0b 7.661.0a, c 0.000
Induced 19.161.9 18.662.7 11.661.1b 9.161.5c 0.000
% differencee 34.867.1* 30.166.7* 23.267.0 17.169.5a 0.012
*p,0.01, paired t test between the basal and induced states.
ap,0.05, Wilcoxon rank-sum test for the NR1I2 groups within each CYP2B6 genotype group.
bp,0.05, Wilcoxon rank-sum test for the CYP2B6 groups with TGT noncarriers.
cp,0.05, Wilcoxon rank-sum test for the CYP2B6 groups with TGT carriers.
dWilcoxon rank-sum test for the CYP2B6 groups; p,0.05 is indicated in bold.
e% difference represents the percent difference between basal and induced state, calculated as an absolute of 1006(induced-basal)/basal.
doi:10.1371/journal.pone.0062489.t004
Figure 1. Effects of NR1I2 TGT and CYP2B6*6 on induction of bupropion hydroxylation by SF. Individual profiles showing AUC_hyd/
AUC_bup ratios for the basal and SF-induced states in the NR1I2 and CYP2B6 genotype groups (n = 33).
doi:10.1371/journal.pone.0062489.g001
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parameter values of bupropion and hydroxybupropion
(AUC_bup, AUC_hyd, and AUC ratio) compared with CYP2B6*6
noncarriers in both the basal and induced states (see Table 4). In
addition, from Fig. 1 and Fig. 2, a tenuous distinction existed in
the concentration (conc.) – time curves of hydroxybupropion and
AUC ratio when TGT carriers appeared; while the curves and
AUC ratio values quickly dropped when CYP2B6*6 carriers came.
This result suggests that CYP2B6*6 variants had stronger reduced
metabolic capacity than NR1I2 TGT haplotype. Interestingly, the
complete mutation-type [CYP2B6*6/*6+NR1I2 TGT+
-24113AA+-24020(-)/(-)] individuals indicated even lower metab-
olism activities (8.761.2 versus 39.568.2) than the complete wild-
types (see Table 2). Therefore, we tentatively conclude that
reduced metabolic capacity is more significant in individuals
including CYP2B6*6 mutations, NR1I2 TGT haplotype, and other
NR1I2 variants with reduced functions.
To date, the verified sites and positions of the SNPs (or
haplotypes) of NR1I2 functional variants were as follows:
-25385C.T (59-UTR), -24622A.T (59-UTR), -24446C.A
(Exon 1), -24113G.A (Intron 1), -24020[GAGAAG].(-) (Intron
1), 106G.A (*2, Exon 3), 2904C.T (*5, Exon 3), 4321G.A (*4,
Exon 4), 4374G.A (*10, Exon 4), 4444A.G (*11, Exon 4),
7635A.G (Intron 5), 8055C.T (Intron 6), 8528G.A (*12, Exon
8), 8561C.T (*7, Exon 8), 9863A.G (*8, Exon 9), 10620C.T
(39-UTR), 10799G.A (39-UTR), 11156A.C (39-UTR),
11193T.C (39-UTR), and NR1I2*1B (8055C.T, Intron
6+2654T.C, 39-UTR) [18,20,42,43,49,50]. However, some
investigations of clinical pharmacogenetics of the NR1I2 functional
variants were not consistent with their findings in vitro. For
instance, NR1I2 -25385C.T, -24113G.A, 7635A.G, or
8055C.T was reported to be associated with higher magnitude
of induction of intestinal CYP3A by rifampin in vitro [18], but
recently, the subjects with -25385C.T or TGT
(-25385T+g.7635G+g.8055T) carriers were verified to have
decreased CYP2B6 activity (AUC ratio) induced by rifampin in
Korean, and NR1I2*1B (8055C.T+2654T.C) haplotype was
strongly associated with its downstream target genes of MDR1 in
Asian breast cancer patients [42]. Moreover, the result for our
subjects with -24113AA showed the lowest percent differences of
AUC ratio (11.367.9) after SF induction compared with wild
genotypes (see Table 3). The specific mechanism of this difference
in vitro and in vivo is yet unknown. However, we must admit that the
result in vitro was easily interfered by diverse uncontrollable factors.
These results highlighted the important role of NR1I2 pharmaco-
genetics in the disposition of putative drug substrates. It can be
assumed that NR1I2 genetic polymorphisms will play an essential
role in affecting interethnic variations in drug disposition.
Previous researches reported that oxysterol, 24(S), 25- epox-
ycholesterol (LXR agonists), glucocorticoid (GR agonists), and
vitamin D (VDR agonists) could induce expression of CYP2B6
through the binding co-activators of the corresponding ligands and
PXR [51–53]. Moreover, gender factor also affected the results of
clinical trials [54,55]. It is worth mentioning that these interference
factors were well balanced through our strict subject exclusion
criteria and good clinical trial control. However, there are also
some deficiencies in our study. For instance, we paid more
attention to the NR1I2 variants, which had the functions reported
in vitro or in vivo such as -25385C.T, -24113G.A, -24020[GA-
GAAG]/(-), 7635A.G, and 8055C.T [18,19,20,42,49,50,56–
58]. The rarely reported or less concerned NR1I2 variants were
not included in this research. Future clinical pharmacogenetics
research of NR1I2 variants should be focused on the reported
functional variants with lower distribution frequencies, which have
potential possibility to play more important roles than the star
variants. In addition, lower concomitance mutation frequencies
and strict subject exclusion criteria also affected our subjects
enrollment. Relatively small and uneven numbers of individuals
with various genotypes were investigated in our study, which were
the limitations of drawing of conclusions based upon this sample
sizes. Further clinical studies of the NR1I2 variants pharmacoge-
Figure 2. Concentration (conc.)–time profiles of hydroxybupropion. Mean plasma concentration-time profiles of hydroxybupropion after
oral administration of 150 mg of bupropion or bupropion+SF treatment in subjects after 14 days in the NR1I2 and CYP2B6 genotype groups.
doi:10.1371/journal.pone.0062489.g002
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netics should be operated in larger groups, and even different
ethnic populations [59].
Conclusions
As the data indicated, NR1I2 TGT haplotype, -24113AA,
CYP2B6*6, and the complete mutation-type [CYP2B6*6/
*6+NR1I2 TGT+ -24113AA+-24020 (-)/(-)] individuals have
strong evidence to show the ability to reduce the metabolic
capacity of CYP2B6 after SF administration in Chinese individuals.
Individuals/ethnic populations with different genetic backgrounds
may show significant differences in drug metabolism and efficacy,
sometimes even manifested as severe adverse drug reactions or no
efficacy. Our findings provide an important reference for carrying
out the gene oriented individual/interethnic therapy of CYP2B6
substrate drugs, and avoiding the adverse effects of SF and
CYP2B6 substrate drugs combination. Whether other NR1I2 and
regulator variants also have impact on the disposition of CYP2B6
substrate drugs by SF requires further exploration. Large-scale
population pharmacokinetic, pharmacodynamic, and nosazontol-
ogy analysis using pharmacogenomics method are needed to
clarify the role of NR1I2 and CYP2B6*6 variants in the efficacy,
safety, and drug interactions of CYP2B6 substrate drugs, even
disease susceptibility between individuals.
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